LAPTM4B and colonic neoplasm: LAPTM4B *2/2 decreased in recurrent patients compared with non-recurrent ones in total colon cancer patients (P = 0.045, 7.4% vs. 20.5%) (Table 1) and in discovery and testing cohort (P = 0.203, 7.1% vs. 22.7% and P = 0.368, 7.6% vs. 17.2%, respectively) (S1 Table).